Japan CAR-T Cell Therapies Market to Hit US$ 1,350.15 Million by 2033 at 16.3% CAGR; Growth Fueled by Rising Hematologic Cancer Cases & Next-Gen Immunotherapies

Market Overview

The Japan CAR-T Cell Therapies Market reached US$ 346.00 million in 2024 and is projected to grow to US$ 1,350.15 million by 2033, registering a CAGR of 16.3% during the forecast period 2025-2033. CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an advanced form of immunotherapy primarily used in the treatment of cancers, especially blood cancers such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma. The therapy involves engineering a patient's T cells to express a chimeric antigen receptor (CAR), enabling them to recognize and destroy cancer cells effectively.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/japan-car-t-cell-therapies-market?Juli

The market demand in Japan is driven by the therapy's ability to provide personalized treatment outcomes and its success in treating relapsed or refractory hematologic malignancies. Research efforts are ongoing to expand CAR-T applications to solid tumors, which present challenges such as a suppressive tumor microenvironment that can reduce therapy efficacy.

Key Developments:

✅ January 2026 - Japan: A leading biopharmaceutical company announced regulatory approval for a next‐generation CAR‐T therapy targeting multiple hematologic malignancies, expanding treatment options for relapsed/refractory leukemia and lymphoma patients in Japan.

✅ October 2025 - Japan: A clinical research consortium launched a Phase II trial evaluating CAR‐T therapy efficacy against solid tumors, marking a significant step toward broadening CAR‐T applications beyond blood cancers.

✅ In January 2024, Bristol Myers Squibb announced three regulatory acceptances from the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for Breyanzi (lisocabtagene maraleucel).

✅ In April 2023, Takara Bio Inc. submitted a Clinical Trial Application (CTA) to Health Canada and the receipt of the No Objection Letter to initiate a Phase I/Ib clinical trial for CD19 JAK/STAT CAR-T therapy (TBI-2001). Once the necessary steps are taken, the investigator-initiated clinical trial will be started for patients with CD19-positive B-cell lymphoma.

✅ In April 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.

Mergers & Acquisitions:

✅ February 2026 - Japan: A leading Japanese biopharmaceutical company acquired a domestic cell therapy production specialist, strengthening its CAR‐T manufacturing capabilities and expanding its commercial footprint in advanced immunotherapies.

✅ November 2025 - Japan: A global cell therapy developer completed the takeover of a Tokyo‐based gene editing startup specializing in CAR‐T engineering platforms, enabling deeper integration of next‐generation constructs into the Japanese market.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=japan-car-t-cell-therapies-market?Juli

Key Players:
Gilead Sciences | Johnson & Johnson Services | Novartis AG | Bristol Myers Squibb Company | Takara Bio Inc.

Key Highlights:

• Gilead Sciences - Holds a 22.5% share, recognized for its leadership in CAR‐T therapy development and commercialization, particularly in hematologic malignancies, supported by strong clinical trial networks and treatment centers across Japan.

• Johnson & Johnson Services - Holds a 18.7% share, leveraging its expertise in cell and gene therapies and partnerships with hospitals and research institutes to deliver innovative CAR‐T solutions for relapsed or refractory blood cancers.

• Novartis AG - Holds a 20.3% share, a pioneer in CAR‐T commercialization with established therapies like Kymriah, driving adoption through strategic collaborations with Japanese healthcare providers.

• Bristol Myers Squibb Company - Holds a 16.5% share, actively developing next‐generation CAR‐T therapies and expanding its clinical trial footprint in Japan to address multiple hematologic and solid tumor indications.

• Takara Bio Inc. - Holds a 12.0% share, focusing on localized CAR‐T manufacturing, process optimization, and research partnerships, particularly in adapting therapies for the Japanese patient population.

Market Segmentation:

By Therapy Type:
The market is segmented into Autologous CAR-T Cell Therapy and Allogeneic CAR-T Cell Therapy. Autologous CAR-T therapy dominates with around 78% share, driven by its proven clinical efficacy and current regulatory approvals in Japan for blood cancers such as ALL and lymphoma. Allogeneic CAR-T therapy holds approximately 22%, representing an emerging segment focused on "off-the-shelf" solutions that aim to reduce production time and expand patient accessibility.

By Drug Type:
Key CAR-T drugs in Japan include Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, and Yescarta. Kymriah leads with about 28% share, being the first CAR-T therapy approved in Japan and widely adopted for pediatric and adult ALL. Yescarta holds roughly 22%, primarily for adult Non-Hodgkin Lymphoma patients. Abecma accounts for 15%, targeting Multiple Myeloma, while Breyanzi and Carvykti each capture around 10%, reflecting growing adoption for lymphoma and myeloma indications. Tecartus represents 5%, with applications in mantle cell lymphoma, and others collectively account for 10%, including pipeline therapies and regional variants.

By Target Antigen:
The market is classified by CD19, BCMA (B-cell maturation antigen), CD20, CD22, CD30, and others. CD19-targeted CAR-T therapies dominate with 55% share, widely used for ALL and various lymphomas. BCMA therapies account for 18%, primarily addressing Multiple Myeloma. CD20 and CD22 targets represent 12% and 7%, respectively, used in Non-Hodgkin and relapsed leukemia treatments. CD30 therapies hold around 3%, focusing on Hodgkin Lymphoma, while other antigen targets collectively account for 5%, reflecting ongoing R&D for novel tumor markers.

By Application:
Applications include Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma (MM), and Follicular Lymphoma. ALL leads with 32% share, driven by high unmet need in relapsed/refractory pediatric and adult patients. Non-Hodgkin Lymphoma represents 28%, reflecting widespread adoption of CD19-targeted therapies. Multiple Myeloma accounts for 20%, supported by BCMA-directed CAR-T therapies. Chronic Lymphocytic Leukemia holds 12%, and Follicular Lymphoma represents 8%, both gradually gaining traction as approvals expand and clinical data supports broader use.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/japan-car-t-cell-therapies-market?Juli
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Insights:

The Kanto region, including Tokyo, Yokohama, and surrounding prefectures, dominates the Japan CAR‐T cell therapy market, accounting for approximately 42% of total market share in 2024. The region's stronghold is driven by the high concentration of leading hospitals, cancer research institutes, and specialized cell therapy centers, as well as collaborations with global CAR‐T developers to facilitate clinical trials and therapy access.

The Kansai region, home to Osaka, Kyoto, and Kobe, holds around 25% market share, supported by growing adoption of CAR‐T therapies in university hospitals and large oncology centers. Kansai's robust healthcare infrastructure and active involvement in clinical research have positioned it as a hub for advanced immunotherapy treatments and CAR‐T clinical trials.

The Chubu region, including Nagoya and surrounding prefectures, contributes nearly 18% of the market, driven by medium-sized hospitals and specialized cancer clinics implementing CAR‐T therapies for blood cancers. The presence of local biopharmaceutical partnerships and regional initiatives to improve advanced therapy delivery are accelerating CAR‐T adoption.

Market Dynamics:

Driver:

Rising Incidence of Hematological Cancers
The increasing prevalence of hematological cancers in Japan, including multiple myeloma, leukemia, and lymphoma, is a key growth driver for the CAR-T cell therapy market. Japan's aging population contributes to a higher incidence of blood-related cancers, creating strong demand for innovative and effective treatment options. For example, according to the International Agency for Research on Cancer, approximately 6,988 new cases of multiple myeloma were reported in Japan in 2022, with projections reaching 7,350 by 2025 and 7,535 by 2030.

Traditional therapies often show limited success in relapsed or refractory cases, raising the adoption of CAR-T therapies, which reprogram a patient's immune cells to specifically target and eliminate cancer cells. Increasing patient awareness, coupled with regulatory approvals of advanced therapies such as CARVYKTI, is strengthening Japan's position as a key CAR-T market in the Asia-Pacific region. These factors collectively drive market growth and support ongoing investment in cell therapy infrastructure.

Restraints:

High Costs of Therapy
The high price of CAR-T cell therapy remains a significant barrier to market growth. The cost of treatment can limit accessibility for patients and strain healthcare budgets, particularly where reimbursement frameworks are incomplete or evolving. Despite proven clinical efficacy, many healthcare providers and insurers are hesitant to cover CAR-T therapy due to uncertainty regarding long-term cost-benefit outcomes, thereby restricting market penetration. This cost constraint continues to challenge broader adoption, especially in smaller hospitals or regions with limited access to advanced cell therapy centers.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.